Clinical trialNCT02426723CompletedPhase 1Interventional

Clinical Study of CWP232291 in Relapsed or Refractory Myeloma Patients

SponsorJW PharmaceuticalEnrollment25Multiple Myeloma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1a/1b, multicenter, open-label, two-part study in subjects with relapsed or refractory MM: * Phase 1a: single agent CWP232291. Dose-finding followed by cohort expansion at the maximum tolerated dose (MTD) or optimal dose as determined by the Safety Review Committee (SRC). * Phase 1b: CWP232291 in combination with lenalidomide and dexamethasone. Dose-finding followed by cohort expansion at the combination therapy MTD or optimal dose as determined by the SRC.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Chang-Ki Min, MD
Seoul St. Mary's Hospital
Principal Investigator
clinicaltrials.gov ↗
Elisabet Manasanch, MD
M.D. Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Jin Seok Kim, MD
Severance Hospital
Principal Investigator
clinicaltrials.gov ↗
Sung-Soo Yoon, MD
Seoul National University Hospital
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Korea

Seoul National University Hospital
Seoul, South Korea
Seoul St.Mary'S Hospital
Seoul, South Korea
Yonsei Severance Hospital
Seoul, South Korea

United States

the University of Texas Md Anderson Cancer Center
Houston, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Phase 1a: CWP232291Phase 1b: CWP232291, Lenalidomide, Dexamethasone

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 19 Oct 2015
Primary completion: 8 Oct 2018
Completion: 26 Oct 2018
Last update posted: 17 May 2019
Registered enrollment: 25
Registry id: NCT02426723

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.